New American Therapeutics

The company's business model centers on acquiring and marketing products for specific physician specialties and associated patient needs. A significant milestone early in its history was the acquisition of the U.S. rights to manufacture, market, and sell Denavir®, a topical antiviral drug for cold sores, from Novartis in October 2010. This acquisition provided a solid financial base for the company. More recently, in April 2022, New American Therapeutics sold the U.S. rights for TOPROL-XL®, a beta-blocker for cardiovascular conditions, to Melinta Therapeutics. This product, indicated for hypertension, angina pectoris, and heart failure, had been a key part of their portfolio. The company's lead product is now in the cardiovascular area.

The current leadership includes CEO Michael Anderson, a 40-year veteran of the pharmaceutical industry, and COO Phillandas Thompson, who has 18 years of experience in the sector. Anderson previously founded Eclat Pharmaceuticals and served as CEO of Avadel Pharmaceuticals. Thompson has held senior legal and strategic roles at companies like Avadel Pharmaceuticals and West-Ward Pharmaceutical. New American Therapeutics is a privately held company and received initial funding through a partnership with Deerfield Management Company, L.P. Keywords: specialty pharmaceutical, drug commercialization, cardiovascular drugs, therapeutic products, pharmaceutical acquisition, Denavir, TOPROL-XL, Alan L. Rubino, Timothy G. Rothwell, Michael Anderson, Phillandas Thompson, Deerfield Management, drug marketing, pharmaceutical business model, branded products, antiviral drugs, beta-blockers, hypertension treatment, angina treatment, heart failure medication